Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Serum anti-p53 antibody is used clinically as a tumor marker of colorectal cancer. However, its prognostic significance in patients with metastatic colorectal cancer (mCRC) remains unclear. KRAS status may influence the host immune response against tumor progression. In the present study, we investigated the prognostic significance of serum anti-p53 in mCRC patients with wild-type KRAS and mutant KRAS treated with systemic chemotherapy.

Methods

A retrospective study of 150 mCRC patients in whom serum anti-p53 antibody was measured before first-line chemotherapy was conducted. The patients were divided into two groups, high p53 and low p53, based on their serum anti-p53 antibody levels. Associations between serum anti-p53 level and clinical outcomes were evaluated in conjunction with KRAS status.

Results

There were 97 (64.7%) patients with wild-type KRAS and 53 (35.3%) with mutant KRAS. In an analysis of all patients, there was no significant difference in overall survival (OS) between the high p53 and low p53 groups. In patients with mutant KRAS, those in the high p53 group exhibited significantly longer OS than those in the low p53 group (p = 0.017, log-rank test). In the multivariate analysis, serum p53 antibody level was an independent predictor of OS in mCRC patients (high vs. normal; hazard ratio 0.438, 95% confidence interval 0.178–0.974, p < 0.05).

Conclusions

Serum anti-p53 antibody level may be an independent predictor of OS in mCRC patients with KRAS mutant tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brody H (2015) Colorectal cancer. Nature 521(7551):S1. https://doi.org/10.1038/521S1a

    Article  PubMed  CAS  Google Scholar 

  2. Jawed I, Wilkerson J, Prasad V et al (2015) Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis. JAMA Oncol 1(6):787–795. https://doi.org/10.1001/jamaoncol.2015.1790

    Article  PubMed  Google Scholar 

  3. Nagai Y, Beppu T, Sakamoto Y et al (2014) Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer. Anticancer Res 34(10):5529–5535

    PubMed  CAS  Google Scholar 

  4. Tokunaga R, Imamura Y, Nakamura K et al (2015) Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma. Cancer Med 4(11):1659–1666. https://doi.org/10.1002/cam4.514

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Aggarwal C, Meropol NJ, Punt CJ et al (2013) Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol 24(2):420–428. https://doi.org/10.1093/annonc/mds336

    Article  PubMed  CAS  Google Scholar 

  6. Narita Y, Taniguchi H, Komori A et al (2014) CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Cancer Chemother Pharmacol 73(2):409–416. https://doi.org/10.1007/s00280-013-2367-7

    Article  PubMed  CAS  Google Scholar 

  7. Shimada H, Shiratori T, Takeda A et al (2009) Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 33(2):272–277. https://doi.org/10.1007/s00268-008-9821-4

    Article  PubMed  Google Scholar 

  8. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9(10):749–758. https://doi.org/10.1038/nrc2723

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Dookeran KA, Dignam JJ, Holloway N et al (2012) Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol 19(7):2334–2344. https://doi.org/10.1245/s10434-011-1934-6

    Article  PubMed  PubMed Central  Google Scholar 

  10. Tokunaga R, Sakamoto Y, Nakagawa S et al (2017) The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surg Today 47(5):636–642. https://doi.org/10.1007/s00595-016-1464-8

    Article  PubMed  CAS  Google Scholar 

  11. Ochiai H, Ohishi T, Osumi K et al (2012) Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today 42(2):164–168. https://doi.org/10.1007/s00595-011-0044-1

    Article  PubMed  CAS  Google Scholar 

  12. Nozoe T, Yasuda M, Honda M et al (2007) Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepatogastroenterology 54(77):1422–1425

    PubMed  CAS  Google Scholar 

  13. Osumi H, Shinozaki E, Suenaga M et al (2015) Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? BMC Cancer 15:760. https://doi.org/10.1186/s12885-015-1751-6

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Did M, Pierantoni GM, Feola A et al (2011) Prognostic significance of N-Cadherin expression in oral squamous cell carcinoma. Anticancer Res 31(12):4211–4218

    Google Scholar 

  15. Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15(6):569–579. https://doi.org/10.1016/S1470-2045(14)70118-4

    Article  PubMed  CAS  Google Scholar 

  16. De Bruijn MT, Raats DA, Tol J et al (2011) Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. Anticancer Res 31(4):1379–1385

    PubMed  Google Scholar 

  17. McShane LM, Altman DG, Sauerbrei W et al (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391. https://doi.org/10.1038/sj.bjc.6602678

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Martincorena I, Campbell PJ (2015) Somatic mutation in cancer and normal cells. Science 349(6255):1483–1489. https://doi.org/10.1126/science.aab4082

    Article  PubMed  CAS  Google Scholar 

  19. Lowe SW, Bodis S, McClatchey A et al (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266(5186):807–810

    Article  CAS  Google Scholar 

  20. Shimada H, Ochiai T, Nomura F et al (2003) Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97(3):682–689. https://doi.org/10.1002/cncr.11092

    Article  PubMed  Google Scholar 

  21. Yamaguchi T, Takii Y, Maruyama S (2014) Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today 44(8):1529–1535. https://doi.org/10.1007/s00595-013-0703-5

    Article  PubMed  CAS  Google Scholar 

  22. Walther A, Johnstone E, Swanton C et al (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489–499. https://doi.org/10.1038/nrc2645

    Article  PubMed  CAS  Google Scholar 

  23. Kressner U, Glimelius B, Bergstrom R et al (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77(11):1848–1851

    Article  CAS  Google Scholar 

  24. Wang P, Liang J, Wang Z et al (2017) The prognostic value of p53 positive in colorectal cancer: a retrospective cohort study. Tumour Biol 39(5):1010428317703651. https://doi.org/10.1177/1010428317703651

    Article  PubMed  CAS  Google Scholar 

  25. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705–5712. https://doi.org/10.1200/JCO.2008.18.0786

    Article  PubMed  CAS  Google Scholar 

  26. Chun YS, Passot G, Yamashita S et al (2017) Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg. https://doi.org/10.1097/SLA.0000000000002450

    Article  PubMed  Google Scholar 

  27. Castedo M, Perfettini JL, Roumier T et al (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23(16):2825–2837. https://doi.org/10.1038/sj.onc.1207528

    Article  PubMed  CAS  Google Scholar 

  28. Vakifahmetoglu H, Olsson M, Zhivotovsky B (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ 15(7):1153–1162. https://doi.org/10.1038/cdd.2008.47

    Article  PubMed  CAS  Google Scholar 

  29. Dietlein F, Kalb B, Jokic M et al (2015) A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer (vol 162, pg 146, 2015). Cell 162(5):1169–1169. https://doi.org/10.1016/j.cell.2015.08.017

    Article  CAS  Google Scholar 

  30. Luo JC, Neugut AI, Garbowski G et al (1995) Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett 91(2):235–240

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank H. Nikki March, PhD, from Edanz Group (https://www.edanzediting.com/ac) for editing a draft of this manuscript.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Nobuya Daitoku, Yuji Miyamoto, Yuki Sakamoto, Ryuma Tokunaga, Yukiharu Hiyoshi, Yohei Nagai, Masaaki Iwatsuki, Shiro Iwagami, Naoya Yoshida & Hideo Baba

Authors
  1. Nobuya Daitoku
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuji Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuki Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryuma Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukiharu Hiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yohei Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaaki Iwatsuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shiro Iwagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Naoya Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hideo Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest in association with the present study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daitoku, N., Miyamoto, Y., Sakamoto, Y. et al. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients. Int J Clin Oncol 25, 651–659 (2020). https://doi.org/10.1007/s10147-019-01599-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-019-01599-4

Keywords

Search

Navigation